Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies.

Dubey D, David WS, Amato AA, Reynolds KL, Clement NF, Chute DF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC.

Neurology. 2019 Aug 12. pii: 10.1212/WNL.0000000000008091. doi: 10.1212/WNL.0000000000008091. [Epub ahead of print]

PMID:
31405908
2.

Prognostic Implications of Co-Occurring Dermatologic and Gastrointestinal Toxicity from Immune Checkpoint Inhibition Therapy for Advanced Malignancies: A Retrospective Cohort Study.

Molina GE, Allen IM, Hughes MS, Zubiri L, Lee H, Mooradian MJ, Reynolds KL, Dougan M, Chen ST.

J Am Acad Dermatol. 2019 Jul 23. pii: S0190-9622(19)32432-6. doi: 10.1016/j.jaad.2019.07.049. [Epub ahead of print] No abstract available.

PMID:
31349048
3.

Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control.

Hughes MS, Zheng H, Zubiri L, Molina GE, Chen ST, Mooradian MJ, Allen IM, Reynolds KL, Dougan M.

Cancer Med. 2019 Jul 9. doi: 10.1002/cam4.2397. [Epub ahead of print]

4.

Predicting malignant potential of subsolid nodules: can radiomics preempt longitudinal follow up CT?

Digumarthy SR, Padole AM, Rastogi S, Price M, Mooradian MJ, Sequist LV, Kalra MK.

Cancer Imaging. 2019 Jun 10;19(1):36. doi: 10.1186/s40644-019-0223-7.

5.

Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum.

Ameri AH, Mooradian MJ, Emerick KS, Park JC, Wirth LJ, Asgari MM, Tsao H, Lawrence D, Sullivan RJ, Demehri S.

Br J Dermatol. 2019 May 18. doi: 10.1111/bjd.18144. [Epub ahead of print] No abstract available.

PMID:
31102460
6.

Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply.

Criss SD, Mooradian MJ, Kong CY.

JAMA Oncol. 2019 Jul 1;5(7):1066-1067. doi: 10.1001/jamaoncol.2019.1100. No abstract available.

PMID:
31095247
7.

The metastatic dissemination of a squamous cell carcinoma arising from an epidermal cyst and subsequent failure to respond to programmed death 1 inhibition.

Lumish MA, Anderson MA, Rush PS, Fintelmann FJ, Duncan L, Sullivan RJ, Mooradian MJ.

JAAD Case Rep. 2019 Apr 5;5(4):375-378. doi: 10.1016/j.jdcr.2019.01.032. eCollection 2019 Apr. No abstract available.

8.

What to Do When Anti-PD-1 Therapy Fails in Patients With Melanoma.

Mooradian MJ, Sullivan RJ.

Oncology (Williston Park). 2019 Apr 15;33(4):141-8. Review.

9.

Clinical characterization of colitis arising from anti-PD-1 based therapy.

Wang DY, Mooradian MJ, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, McKee S, Norrell JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z, Sullivan R, Johnson DB.

Oncoimmunology. 2018 Oct 31;8(1):e1524695. doi: 10.1080/2162402X.2018.1524695. eCollection 2019.

PMID:
30546965
10.

Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.

Criss SD, Mooradian MJ, Sheehan DF, Zubiri L, Lumish MA, Gainor JF, Reynolds KL, Kong CY.

JAMA Oncol. 2019 Mar 1;5(3):358-365. doi: 10.1001/jamaoncol.2018.5449.

PMID:
30543349
11.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, Abbate KT, Menzies AM, Johnson DB, Sullivan RJ, Shoushtari AN.

Cancer. 2019 Mar 15;125(6):884-891. doi: 10.1002/cncr.31889. Epub 2018 Dec 6.

PMID:
30521084
12.

Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experience.

Mooradian MJ, Nasrallah M, Gainor JF, Reynolds KL, Cohen JV, Lawrence DP, Miloslavsky EM, Kohler MJ, Sullivan RJ, Schoenfeld SR.

Semin Arthritis Rheum. 2019 Jun;48(6):1127-1132. doi: 10.1016/j.semarthrit.2018.10.012. Epub 2018 Oct 16.

PMID:
30409415
13.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer.

Dagogo-Jack I, Azzolli CG, Fintelmann F, Mino-Kenudson M, Farago AF, Gainor JF, Jiang G, Piotrowska Z, Heist RS, Lennes IT, Temel JS, Mooradian MJ, Lin JJ, Digumarthy SR, Batten JM, Robinson H, Nose V, Rivera M, Nardi V, Dias-Santagata D, Le LP, Sequist LV, Pitman M, Shepard JO, Shaw AT, Iafrate AJ, Lennerz JK.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00299. Epub 2018 Jul 24.

14.

Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.

Zhang ML, Kem M, Mooradian MJ, Eliane JP, Huynh TG, Iafrate AJ, Gainor JF, Mino-Kenudson M.

Mod Pathol. 2019 Apr;32(4):511-523. doi: 10.1038/s41379-018-0160-1. Epub 2018 Oct 26.

PMID:
30367104
15.

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ.

Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.

16.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
17.

Putting the brakes on CTLA-4 inhibition in lung cancer?

Mooradian MJ, Gainor JF.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S35-S38. doi: 10.21037/tlcr.2018.01.05. No abstract available.

18.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Erratum in: Eur J Cancer. 2018 Mar 13;:.

19.

Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.

Mooradian MJ, Sullivan RJ.

Future Oncol. 2017 Aug;13(18):1649-1663. doi: 10.2217/fon-2017-0117. Epub 2017 Aug 4. Review.

PMID:
28776423
20.

ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack.

Mooradian MJ, Gainor JF.

Oncologist. 2017 Jul;22(7):759-761. doi: 10.1634/theoncologist.2017-0178. Epub 2017 Jun 22. No abstract available.

21.

Clonal Evolution and the Role of Serial Liquid Biopsies in a Case of Small-Cell Lung Cancer-Transformed EGFR Mutant Non-Small-Cell Lung Cancer.

Mooradian MJ, Piotrowska Z, Drapkin BJ, Dias-Santagata D, Marcoux N, Arnaoutakis K, Nagy RJ, Lanman R, Iafrate AJ, Farago AF, Mino-Kenudson M, Hata AN, Sequist LV.

JCO Precis Oncol. 2017;1. doi: 10.1200/PO.17.00123. Epub 2017 Nov 7. No abstract available.

Supplemental Content

Loading ...
Support Center